Herpes simplex virus type 1 thymidine kinase SR39 mutant (HSV1-tk SR39) (HSV1-tk SR39)

The Herpes simplex virus type 1 thymidine kinase SR39 mutant (HSV1-tk SR39) is an engineered enzyme widely utilized as a suicide gene in cancer therapy and a reporter gene in molecular imaging. Developed through semi-random mutagenesis, the SR39 variant exhibits a significantly higher affinity (approximately 14-fold lower Km for ganciclovir) and improved catalytic efficiency for nucleoside analogs compared to the wild-type HSV1-tk enzyme. In therapeutic applications, the gene encoding SR39 is delivered to target cells, such as tumor cells, which then express the enzyme and become selectively sensitive to prodrugs like valganciclovir. Upon administration, SR39 phosphorylates the prodrug into a monophosphate form, which is further processed by host kinases into a toxic triphosphate that inhibits DNA synthesis and triggers apoptosis. Additionally, SR39 serves as a highly sensitive reporter for positron emission tomography (PET) imaging, where it traps radiolabeled probes like [18F]FHBG to allow for the non-invasive monitoring of gene delivery and expression levels in vivo. Its enhanced kinetics allow for the use of lower, less immunosuppressive doses of prodrugs while maintaining high therapeutic efficacy.

Other names

SR39 mutantsr39TKHSV1-sr39tkMutant thymidine kinase SR39HSV-tk SR39

The SR39 mutant enzyme catalyzes the initial, rate-limiting phosphorylation of nucleoside analog prodrugs, such as ganciclovir (derived from valganciclovir), into their monophosphate forms. These monophosphates are subsequently converted by endogenous host cellular kinases into cytotoxic triphosphate metabolites. These active metabolites compete with natural deoxyguanosine triphosphate (dGTP) for incorporation into nascent DNA strands by DNA polymerase, leading to premature chain termination and the induction of apoptosis in the target cells.